Mark A. Goldberg
Independent DirectorDr. Mark A. Goldberg, M.D., served as Executive Chairman at Definitive Media Corp. (formerly known as THREAD) until February 2026. Dr. Goldberg is Operating Partner of Arsenal Capital Management LP from January 2026. He served as an Executive Advisor at Water Street Healthcare Partners, LLC since November 2018. He serves as an Independent Director at Intensity Therapeutics, Inc. since May 2018. Dr. Goldberg has been the Executive Chairman of Allucent (formerly known as Cato Research Ltd.). since April 3, 2018 and also served as its Chief Executive Officer until July 2024. He serves on the board of directors of Intensity Therapeutics, Inc. He is a senior life science executive and innovator. He served as the President and Chief Operating Officer of PAREXEL International Corporation since July 1, 2012 until 2018 and July 2008 until 2018 respectively. Dr. Goldberg served as Chief Operating Officer of Parexel Informatics, Inc. He was instrumental in driving business results through the application of his combined medical, technical and clinical research expertise. He served in management capacities of increasing responsibility at Genzyme from 1996 to 2011, including as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg served as the President of Clinical Research Services business segment of Parexel International Corporation from June 2005 to July 2008. Dr. Goldberg served as the President of Perceptive Informatics at PAREXEL International Corporation from July 2000 to August 2008. He co-founded PAREXEL Informatics, Inc. in 2000 and served as its President from July 2000 to August 2008. From July 1999 to July 2000, he served as Senior Vice President of Parexel International Corporation's Clinical Research Services business and was responsible for managing the Advanced Technology and Informatics Group subdivision, which included IT applications support for both internal operations and external clients. He also oversaw the geographic expansion of the company clinical development capabilities, including significant growth in the Asia-Pacific region. He joined PAREXEL in 1997 as Vice President and established its medical imaging group-seeking to leverage imaging data as a surrogate endpoint in evaluating the safety and efficacy of new products. He served as President of WorldCare, Inc. Dr. Goldberg served as President of the American Telemedicine Association from 1998 to 2000. He was the founding Editor-in-Chief of the peer-reviewed Telemedicine Journal. He served as a Director of the American Telemedicine Association. He served as a Director of WorldCare Inc. He completed residency training in Diagnostic Radiology at Massachusetts General Hospital (MGH) where he served as Chief Resident. He was a Staff Radiologist at MGH and maintained an appointment as Consultant in Radiology. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School. In 2012, he received the Special Recognition Award from the Academy of Physicians in Clinical Research for advancing clinical research through a combination of medical knowledge, development expertise and information technology. He is a board-certified medical oncologist and hematologist and has published more than 50 papers. In 2011, he was recognized by The Week magazine in its list of the world top emerging business leaders. He completed residency training in Diagnostic Radiology at MGH. Dr. Goldberg holds BS degree in Computer Science and Engineering from Massachusetts Institute of Technology and received his MD degree from the University of Massachusetts Medical School.
Positions
- Company NameIntensity Therapeutics, Inc.Stock CodeINTSPositionIndependent DirectorColleagues
- LHLewis H. BenderFounder, President, CEO & Chairman of the Board
- JTJoseph TalamoChief Financial Officer
- JWJohn WesolowskiPrincipal Accounting Officer & Controller
- JMJames M. AhlersExecutive Vice President of Corporate Finance
- ELEmer LeahyIndependent Director
- DJDaniel J. DonovanIndependent Director
- RLRiccardo LencioniMember of Scientific Advisory Board
